2nd email to Andy Robinson, Managing Director, Publishing at CABI. This Petition Update is a follow-up to yesterday's update: Is CABI promoting a false public health narrative?
---------- Original Message ----------
From: CARL TUTTLE <runagain@comcast.net>
To: "a.robinson@cabi.org" <a.robinson@cabi.org>, "microbialservices@cabi.org" <microbialservices@cabi.org>
Cc: "a.lainsbury@cabi.org" <a.lainsbury@cabi.org>, "a.thompson@cabi.org" <a.thompson@cabi.org>, "c.ashby@cabi.org" <c.ashby@cabi.org>, "d.bird@cabi.org" <d.bird@cabi.org>, "h.fielder@cabi.org" <h.fielder@cabi.org>, "j.cullum@cabi.org" <j.cullum@cabi.org>, "j.porciello@cabi.org" <j.porciello@cabi.org>, "r.schoelzel@cabi.org" <r.schoelzel@cabi.org>, "w.cooper@cabi.org" <w.cooper@cabi.org>, "h.jansen@cabi.org" <h.jansen@cabi.org>, "k.shirley@cabi.org" <k.shirley@cabi.org>, "support@cabi.org" <support@cabi.org>
Date: 08/27/2025 8:56 AM EDT
Subject: Re: Is CABI promoting a false public health narrative?
Dear Dr. Robinson,
As a follow-up to my previous email please see the following correspondence sent to Adriana Marques who refused to respond like many of the other authors in the Publication: Lyme Disease: An Evidence-based Approach acting as an autonomous group where its authority is absolute, cannot be challenged and answer only to themselves.
Respectfully Submitted,
Carl Tuttle
Independent Researcher
Hudson, NH
Correspondence sent to Adriana Marques:
---------- Original Message ----------
From: CARL TUTTLE <runagain@comcast.net>
To: "amarques@niaid.nih.gov" <amarques@niaid.nih.gov>
Cc: "osmith@aaas.org" <osmith@aaas.org>, "mnorton@aaas.org" <mnorton@aaas.org>, "ccharneski@aaas.org" <ccharneski@aaas.org>, "cmalo@aaas.org" <cmalo@aaas.org>, "bberry@aaas.org" <bberry@aaas.org>, "dhallberg@aaas.org" <dhallberg@aaas.org>, "dneuhofer@aaas.org" <dneuhofer@aaas.org>, "mogle@aaas.org" <mogle@aaas.org>
Date: 11/14/2024 9:54 AM EST
Subject: Symptoms after Lyme disease: What’s past is prologue
SCIENCE TRANSLATIONAL MEDICINE
13 Nov 2024
Symptoms after Lyme disease: What’s past is prologueADRIANA MARQUES
https://www.science.org/doi/10.1126/scitranslmed.ado2103
“There have been five randomized, placebo-controlled, double-blind clinical trials addressing the question of whether additional antibiotic treatment benefits patients with PTLDS or symptoms attributed to Lyme disease.”
“The results of these trials showed that prolonged antibiotic treatment had no lasting benefit while having potential serious risks.”
Adriana Marques, M.D.
Lyme Disease Studies Unit
NIH Main Campus, Bethesda, MD
Dr. Marques,
For the record there are many infections requiring long-term antibiotics so why Klempner stopped his NIH funded antibiotic treatment trials for Lyme after “12 weeks” and then claimed no benefit makes absolutely no sense whatsoever:
From the following peer-reviewed publication:
Benefit of intravenous antibiotic therapy in patients referred for treatment of neurologic Lyme disease
https://www.dovepress.com/benefit-of-intravenous-antibiotic-therapy-in-patients-referred-for-tre-peer-reviewed-fulltext-article-IJGM
Infections requiring long-term antibiotics:
[See chart HERE]
In 1991 the Lyme disease organism, Borrelia burgdorferi, was grown from the cerebrospinal fluid of Lyme patient Vicki Logan at the Centers for Disease Control in Fort Collins, Colorado despite prior treatment with intravenous antibiotics. The patient died when the insurer refused additional IV antibiotics. Here is a copy of Logan’s CDC positive culture report for your review.
(Vicki Logan’s Chronic Lyme Autopsy results Page #1, 2, 3, 4, 5, 6, 7)
There are 700 peer-reviewed publications referencing persistent infection and in a 2018 study all patients were culture positive even after multiple years on antibiotics so there was no relief from current antimicrobials. Some of these patients had taken as many as eleven different types of antibiotics.
Thirty-four years ago Dr. Allen Steere identified chronic Lyme disease which should have set off a red flag prompting an immediate search for better antimicrobials but then did a 180° as he became principal investigator (PI) of the Phase 3 clinical trial for the first Lyme disease vaccine. So all the eggs were put into the vaccine basket while a campaign was orchestrated to discredit the sick and disabled patient population along with the courageous clinicians attempting to help these patients. Apparently, a chronic relapsing seronegative disease did not fit the business model of patent royalties, vaccine development and pharmaceutical profits.
Here is Dr. Steere’s 1990 publication summary for your review:
The New England Journal of Medicine
Published November 22, 1990
Chronic neurologic manifestations of Lyme disease
https://www.nejm.org/doi/full/10.1056/NEJM199011223232102
The chart below summarizes Lyme research funded by the NIH and only 2.5% has been allocated for treatment:
[See chart HERE]
Question:
Is there a reason why these facts/references/lab reports are missing from your viewpoint published in Science Translational Medicine?
A response to this inquiry is requested.
Carl Tuttle
Independent Researcher
Hudson, NH USA
Cc: Orla M. Smith, Ph.D. Editor, Science Translational Medicine
Editorial Staff
Melissa Norton, M.D.
Catherine A. Charneski, Ph.D.
Courtney S. Malo, Ph.D.
Brandon Berry, Ph.D.
Dorothy L. Hallberg, Ph.D.
Daniela Neuhofer, Ph.D.
Molly Ogle, Ph.D.